The Therapeutic Implications of EML4/ALK, ROS-1 and Other New Biomarkers Lyudmila Bazhenova, MD Associate Clinical Professor Lung Cancer Unit Leader UC.
UNIVERSITY OF TORINO – DEPARTMENT OF ONCOLOGY Treatment of ALK- and ROS-1 translocated NSCLC Massimo Di Maio, MD Department of Oncology, University of.
The Therapeutic I mplications of EML4/ALK, ROS-1 and Other N ew Biomarkers
